2023 World Conference on Lung Cancer (Posters)-P2.31. Clinical Outcomes of Real-World Treatment for Metastatic EGFRm NSCLC after Osimertinib and Platinum-Based Chemotherapy

P2.31. Clinical Outcomes of Real-World Treatment for Metastatic EGFRm NSCLC after Osimertinib and Platinum-Based Chemotherapy - PDF(Slides)

Back to course

Pdf Summary

This study utilized the Flatiron Health electronic health record (EHR) database to analyze the clinical outcomes of real-world treatment for patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC) after receiving osimertinib and platinum-based chemotherapy. The study included data from approximately 280 cancer clinics across the United States.<br /><br />The selection criteria for patients included a diagnosis of metastatic NSCLC with an activating EGFR mutation, initiation of a new line of therapy after treatment with osimertinib and platinum-based chemotherapy, and a non-missing ECOG performance status of 1. Patients with certain medical conditions and prior treatment with specific therapies were excluded. <br /><br />Two cohorts were defined for analysis: the matched cohort, which was designed to mimic the eligibility criteria of patients in the HL-01 trial, and the exploratory matched cohort, which consisted of patients with two response assessments 28 days apart. Propensity score weighting was used to ensure a similar distribution of baseline characteristics between the cohorts.<br /><br />The study evaluated real-world overall survival (rwOS), real-world progression-free survival (rwPFS), and confirmed real-world objective response rate (rwORR). Descriptive statistics and Kaplan-Meier methods were used to analyze the data.<br /><br />The results showed that the median rwPFS in the matched cohort was 4.2 months, and the median rwOS was 9.1 months. The confirmed rwORR in the exploratory matched cohort was 14.1%. These outcomes indicate that currently available therapies provide limited benefit for patients with EGFR-mutated NSCLC after osimertinib and platinum-based chemotherapy.<br /><br />The study acknowledges its limitations, including a small sample size for the analysis of confirmed rwORR and the possibility that the response subset may represent a specific population with favorable outcomes compared to the overall population.<br /><br />Overall, this study provides valuable real-world data on the clinical outcomes of treatment for patients with metastatic EGFR-mutated NSCLC after failure of osimertinib and platinum-based chemotherapy. These findings highlight the need for effective treatment options in this setting.

Asset Subtitle

Jyoti Patel

Meta Tag

Speaker Jyoti Patel

Topic Global Health, Health Services & Health Economics: Real World Data

Keywords

Flatiron Health

electronic health record

EHR database

metastatic EGFR-mutated non-small cell lung cancer

osimertinib

platinum-based chemotherapy

clinical outcomes

real-world treatment

cancer clinics

United States